Member Info for market_magic

Looking back across the RNS's there is some concern about how long this will take to reach market. China is 2 years and the U.S. require a study that will also take about 2 years to complete before being allowed to distribute. A U.S. deal might come and with it cash up-front (I guess) - wonder of they will have to re-raise cash before then (?)

These results are significant. It's a win-win situation - reduced cost and fewer people taking up beds in hospitals for IV treatments.

... 50m bonus pay out to Tim Steiner, group loss of 40m - brilliant!

... don't fall for it.

Did I hear right i the presentation that they would have to wait 2-3 years for another study to be concluded in China before the product could be rolled out?

EPRA NAV per share of 856p (Sep 2019) - brilliant!

Cruise business accounts for 20% of SAGA's business.

...errrr.

If the predictions about how much the US will be affected by COVID-19, do you think the U.S. will be "go away, we have more important things to deal with right now", or that they would push this through in order to help the bed situation?

The 1-2billion net profit it will be getting once it has built all of the fulfilment centres as a result of being paid a percentage of revenues from it's partner retailers.

This RNS is not an easy read. Could you just clarify if I have this correct?
- This study was for non-inferiority.
- The PP result concluded that Feraccru®/Accrufer® was deemed non-inferior to other treatments (which is a good thing).
- The ITT result concluded that Feraccru®/Accrufer® was deemed inferior to other treatments, however, ITT isn't regarded as a reliable trial method.
- Feraccru®/Accrufer® is, therefore, a non-inferior treatment method.
- Previous, independent trials have given STX the rights to market Feraccru®/Accrufer®.
- The commercial agreements already in place would have known that the PP study is a good indication of the efficacy of the treatment and the ITT results are fairly irrelevant.

Does Accrufer mean that it will make treatment more affordable and will become a favourite in the medical world if IV's are no longer needed? Or, in privatised healthcare systems like the U.S, is it likely to be bought up and marked up by the middlemen you exploit those that need it?

https://www.advisory.com/daily-briefing/2019/08/07/iron-injections

!?

June - brilliant... just when they'l need to raise some more cash. What goes up, must come down.

Is there any specific reason that my platform would not allow me to trade yesterday? I have lost £1,300 by missing out on not being able to sell yesterday.

Some of the lithium alternative battery tech currently being researched relies on Nickel.

Is PAL not just an experiment by KLK to see if a fully-sustainable production operation in West Africa can sustain itself? Lots of pressure on Palm Oil to be harvested sustainably, so if this is the case, I can see KLK selling it but expanding it (?)

Why are they al objecting to fracking?

1,350,000 shares isn't really exactly showing faith.